Regulatory and clinical considerations for biosimilar oncology drugs

C. L. Bennett, B. Chen, M. D. Wyatt, R. M. Schulz, P. Georgantopoulos, S. Kessler, Z. P. Qureshi, Z. K. Lu, B. L. Love, V. Noxon, J. Bian, P. Ray, R. J. Ablin, W. J. Hruskesky, T. Hermanson, D. W. Raisch, L. Bobolts, M. Armitage, W. J. Hrushesky, I. C. Macdougall & 2 others O. Sartor, James Olen Armitage

Research output: Contribution to journalReview article

64 Citations (Scopus)

Abstract

Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological drugs-provide opportunities both to improve health-care access and outcomes, and to reduce costs. Several international regulatory pathways have been developed to expedite entry of biosimilars into global marketplaces. The first wave of oncology biosimilar use was in Europe and India in 2007. Oncology biosimilars are now widely marketed in several countries in Europe, and in Australia, Japan, China, Russia, India, and South Korea. Their use is emerging worldwide, with the notable exception of the USA, where several regulatory and cost barriers to biosimilar approval exist. In this Review, we discuss oncology biosimilars and summarise their regulatory frameworks, clinical experiences, and safety concerns.

Original languageEnglish (US)
Pages (from-to)e594-e605
JournalThe Lancet Oncology
Volume15
Issue number13
DOIs
StatePublished - Jan 1 2014

Fingerprint

Biosimilar Pharmaceuticals
Pharmaceutical Preparations
Costs and Cost Analysis
India
Safety
Insurance Carriers
Republic of Korea
Health Services Accessibility
Russia
China
Japan

ASJC Scopus subject areas

  • Oncology

Cite this

Bennett, C. L., Chen, B., Wyatt, M. D., Schulz, R. M., Georgantopoulos, P., Kessler, S., ... Armitage, J. O. (2014). Regulatory and clinical considerations for biosimilar oncology drugs. The Lancet Oncology, 15(13), e594-e605. https://doi.org/10.1016/S1470-2045(14)70365-1

Regulatory and clinical considerations for biosimilar oncology drugs. / Bennett, C. L.; Chen, B.; Wyatt, M. D.; Schulz, R. M.; Georgantopoulos, P.; Kessler, S.; Qureshi, Z. P.; Lu, Z. K.; Love, B. L.; Noxon, V.; Bian, J.; Ray, P.; Ablin, R. J.; Hruskesky, W. J.; Hermanson, T.; Raisch, D. W.; Bobolts, L.; Armitage, M.; Hrushesky, W. J.; Macdougall, I. C.; Sartor, O.; Armitage, James Olen.

In: The Lancet Oncology, Vol. 15, No. 13, 01.01.2014, p. e594-e605.

Research output: Contribution to journalReview article

Bennett, CL, Chen, B, Wyatt, MD, Schulz, RM, Georgantopoulos, P, Kessler, S, Qureshi, ZP, Lu, ZK, Love, BL, Noxon, V, Bian, J, Ray, P, Ablin, RJ, Hruskesky, WJ, Hermanson, T, Raisch, DW, Bobolts, L, Armitage, M, Hrushesky, WJ, Macdougall, IC, Sartor, O & Armitage, JO 2014, 'Regulatory and clinical considerations for biosimilar oncology drugs', The Lancet Oncology, vol. 15, no. 13, pp. e594-e605. https://doi.org/10.1016/S1470-2045(14)70365-1
Bennett CL, Chen B, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S et al. Regulatory and clinical considerations for biosimilar oncology drugs. The Lancet Oncology. 2014 Jan 1;15(13):e594-e605. https://doi.org/10.1016/S1470-2045(14)70365-1
Bennett, C. L. ; Chen, B. ; Wyatt, M. D. ; Schulz, R. M. ; Georgantopoulos, P. ; Kessler, S. ; Qureshi, Z. P. ; Lu, Z. K. ; Love, B. L. ; Noxon, V. ; Bian, J. ; Ray, P. ; Ablin, R. J. ; Hruskesky, W. J. ; Hermanson, T. ; Raisch, D. W. ; Bobolts, L. ; Armitage, M. ; Hrushesky, W. J. ; Macdougall, I. C. ; Sartor, O. ; Armitage, James Olen. / Regulatory and clinical considerations for biosimilar oncology drugs. In: The Lancet Oncology. 2014 ; Vol. 15, No. 13. pp. e594-e605.
@article{fbfbd668a3ce453189a9e2db786f9644,
title = "Regulatory and clinical considerations for biosimilar oncology drugs",
abstract = "Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological drugs-provide opportunities both to improve health-care access and outcomes, and to reduce costs. Several international regulatory pathways have been developed to expedite entry of biosimilars into global marketplaces. The first wave of oncology biosimilar use was in Europe and India in 2007. Oncology biosimilars are now widely marketed in several countries in Europe, and in Australia, Japan, China, Russia, India, and South Korea. Their use is emerging worldwide, with the notable exception of the USA, where several regulatory and cost barriers to biosimilar approval exist. In this Review, we discuss oncology biosimilars and summarise their regulatory frameworks, clinical experiences, and safety concerns.",
author = "Bennett, {C. L.} and B. Chen and Wyatt, {M. D.} and Schulz, {R. M.} and P. Georgantopoulos and S. Kessler and Qureshi, {Z. P.} and Lu, {Z. K.} and Love, {B. L.} and V. Noxon and J. Bian and P. Ray and Ablin, {R. J.} and Hruskesky, {W. J.} and T. Hermanson and Raisch, {D. W.} and L. Bobolts and M. Armitage and Hrushesky, {W. J.} and Macdougall, {I. C.} and O. Sartor and Armitage, {James Olen}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/S1470-2045(14)70365-1",
language = "English (US)",
volume = "15",
pages = "e594--e605",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "13",

}

TY - JOUR

T1 - Regulatory and clinical considerations for biosimilar oncology drugs

AU - Bennett, C. L.

AU - Chen, B.

AU - Wyatt, M. D.

AU - Schulz, R. M.

AU - Georgantopoulos, P.

AU - Kessler, S.

AU - Qureshi, Z. P.

AU - Lu, Z. K.

AU - Love, B. L.

AU - Noxon, V.

AU - Bian, J.

AU - Ray, P.

AU - Ablin, R. J.

AU - Hruskesky, W. J.

AU - Hermanson, T.

AU - Raisch, D. W.

AU - Bobolts, L.

AU - Armitage, M.

AU - Hrushesky, W. J.

AU - Macdougall, I. C.

AU - Sartor, O.

AU - Armitage, James Olen

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological drugs-provide opportunities both to improve health-care access and outcomes, and to reduce costs. Several international regulatory pathways have been developed to expedite entry of biosimilars into global marketplaces. The first wave of oncology biosimilar use was in Europe and India in 2007. Oncology biosimilars are now widely marketed in several countries in Europe, and in Australia, Japan, China, Russia, India, and South Korea. Their use is emerging worldwide, with the notable exception of the USA, where several regulatory and cost barriers to biosimilar approval exist. In this Review, we discuss oncology biosimilars and summarise their regulatory frameworks, clinical experiences, and safety concerns.

AB - Biological oncology products are integral to cancer treatment, but their high costs pose challenges to patients, families, providers, and insurers. The introduction of biosimilar agents-molecules that are similar in structure, function, activity, immunogenicity, and safety to the original biological drugs-provide opportunities both to improve health-care access and outcomes, and to reduce costs. Several international regulatory pathways have been developed to expedite entry of biosimilars into global marketplaces. The first wave of oncology biosimilar use was in Europe and India in 2007. Oncology biosimilars are now widely marketed in several countries in Europe, and in Australia, Japan, China, Russia, India, and South Korea. Their use is emerging worldwide, with the notable exception of the USA, where several regulatory and cost barriers to biosimilar approval exist. In this Review, we discuss oncology biosimilars and summarise their regulatory frameworks, clinical experiences, and safety concerns.

UR - http://www.scopus.com/inward/record.url?scp=84924854592&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924854592&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(14)70365-1

DO - 10.1016/S1470-2045(14)70365-1

M3 - Review article

VL - 15

SP - e594-e605

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 13

ER -